Intercure Ltd.
INCRIntercure Ltd. in brief
Intercure Ltd. is a listed company in the Biotechnology industry, based in Israel. Its market value was $51 M on 1 August 2026, which makes it the 21,184th largest listed company in the world and the 230th largest in Israel on this site. In the year to December 2024 it had sales of $65 M and a net loss of $18 M. Alexander Rabinovich is its chief executive. Its largest business segments by sales in 2025 were Cannabis segment (100%). Its shares trade under the symbol INCR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Intercure Ltd.
InterCure Ltd. is an Israeli public corporation incorporated in November 1994 under the Israeli Companies Ordinance [New Version] 5743-1983. Our shares are listed for trading on the Nasdaq under the symbol “INCR” and on the TASE under the symbol “INCR”. Our principal executive offices are located at 85 Medinat ha Yehudim Street, 4676670 Israel. Our telephone number in Israel is +972 77 460 5012. Our website address is http://www.intercure.co. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this Annual Report, and the reference to our website in this Annual Report is an inactive textual reference only. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our filings with the SEC will also be available to the public through the SEC’s website at www.sec.gov.
From the company's annual report filed with the US SEC: read the report
Intercure Ltd. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Intercure Ltd. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #176 (Jan 2020) · #197 (Jan 2021) · #214 (Jan 2022) · #219 (Dec 2022) · #312 (Jul 2023) · #305 (Jan 2024) · #39 (Mar 2026) · #232 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.8×
- Price / book
- 0.5×
- Free cash flow yield
- -37.4%
- Net margin (TTM)
- -28.4%
- Operating margin
- -28.1%
- Return on equity
- -16.8%
- Liabilities / assets
- 47.9%
- Net debt
- $10M
- Revenue growth
- -33.0%
- R&D / revenue
- 0.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $65M | -33.0% | $-18M | $-18M | -28.4% |
| Dec 2023 | $96M | -16.6% | $-11M | $-17M | -17.4% |
| Dec 2022 | $116M | +70.0% | $15M | $13M | 11.5% |
| Dec 2021 | $68M | +259.7% | $9M | $1M | 2.1% |
| Dec 2020 | $19M | +656.4% | $-11M | $-11M | -57.2% |
| Dec 2019 | $3M | — | $-1M | $-2M | -66.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-18M | $1M | $-19M | $-0.40 | — |
| Dec 2023 | $-15M | $1M | $-15M | $-0.37 | — |
| Dec 2022 | $15M | $6M | $9M | $0.29 | — |
| Dec 2021 | $9M | $4M | $5M | $0.03 | — |
| Dec 2020 | $2M | $6M | $-4M | $-0.41 | — |
| Dec 2019 | $-3M | $8M | $-11M | $-0.07 | — |
SEC filings
- Sep 8, 20266-KReport of foreign issuer
- Aug 26, 20266-KReport of foreign issuer
- Aug 24, 20266-KReport of foreign issuer
- Aug 11, 20266-KReport of foreign issuer
- Aug 4, 20266-KReport of foreign issuer
- Jul 22, 20266-KReport of foreign issuer
- Jun 22, 20266-KReport of foreign issuer
- Jun 15, 20266-KReport of foreign issuer
- May 1, 20266-KReport of foreign issuer
- Apr 30, 202620-FAnnual report (foreign issuer) · period to Dec 2025
- Mar 3, 20266-KReport of foreign issuer
- Feb 19, 20266-KReport of foreign issuer
Official filings of Intercure Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $65 M
- Operating income
- $-18 M
- Net income
- $-18 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $209 M
- Total liabilities
- $100 M
- Total equity
- $109 M
As of December-2024
Top 11 institutional investors in Intercure Ltd.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Healthcare Of Ontario Pension Plan Trust Fund | 42,500 | New | $0 M | Nov 13, 2026 |
| 2 | Moore Capital Management, LP | 19,454 | New | $0 M | Nov 16, 2026 |
| 3 | Citadel Advisors LLC | 10,312 | New | $0 M | Nov 16, 2026 |
| 4 | Jane Street Group, LLC | 10,129 | New | $0 M | Nov 12, 2026 |
| 5 | BlackRock, Inc. | 4,098 | New | $0 M | Nov 13, 2026 |
| 6 | Quent Capital, LLC | 2,064 | New | $0 M | Nov 13, 2026 |
| 7 | Morgan Stanley | 1,000 | New | $0 M | Nov 13, 2026 |
| 8 | UBS Group AG | 258 | New | $0 M | Nov 10, 2026 |
| 9 | Tower Research Capital LLC (TRC) | 91 | New | $0 M | Nov 16, 2026 |
| 10 | Jpmorgan Chase & Co | 54 | New | $0 M | Nov 12, 2026 |
| 11 | Royal Bank Of Canada | 39 | New | $0 M | Nov 16, 2026 |
Markets and events: Intercure Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-08-24 13:32 UTC, code LUDP, resumed 13:37 UTC
- 2026-08-21 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 54 shares at $5.10
- : 4 shares at $5.31
- : 971 shares at $5.39
- : 1 shares at $5.13
- : 6 shares at $5.29
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Intercure Ltd. scorecard#
Passes 2 of the 13 checks that could be worked out: strongest in profitability (1 of 5), weakest in growth (0 of 6). Fiscal year 2024; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 6
- ✗Revenue grew in the newest year-33.0%Revenue down 33.0% in fiscal 2024.
- ✗Revenue up more than 5% a year over three years-1.7%-1.7% a year over the three years to fiscal 2024.
- ✗Faster growth over three years than its peers' median-1.7%-1.7% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.40 vs -0.37Diluted EPS -0.40 in fiscal 2024 against -0.37 the year before (report's currency).
- ✗Net income higher than five years earlier-$18 M-$18 M in fiscal 2024 against -$2 M in 2019.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2024.
Profitability1 of 5
- ✗Profitable in the newest year-$18 MNet income -$18 M in fiscal 2024.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2024.
- ✓Operating margin above its peers' median-28.1%-28.1% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-15.6%-15.6% in fiscal 2024.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-28.1%-28.1% in fiscal 2024 against 12.8% in 2021.
Financial health1 of 2
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- ✓Debt below equity0.3×Debt to equity 0.29 at the end of fiscal 2024.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Intercure Ltd.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | -28.1% | -60.5% | |
| Net margin | -28.4% | -68.9% | |
| Return on equity | -15.6% | -61.0% | |
| Revenue growth, 3 years a year | -1.7% | 12.9% | |
| Revenue growth | -33.1% | 15.8% | |
| Debt to equity | 0.29× | 0.26× |
1of 8on the Piotroski tests of financial strength
- Revenue fell 33.0% against the year before.
- Net loss of $18 million.
- Free cash flow was negative: -$19 million.
Intercure Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in ILS millions; per-share figures in ILS; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 239−32.8%100% | 356−8.5%100% | 389+76.9%100% | 220+238%100% | 65+629%100% | 8.9—100% | |
| Cost of revenue | 203−17.8%85.1% | 247+7.6%69.5% | 230+85.7%59.1% | 124+257%56.3% | 35+365%53.3% | 7.5—83.5% | |
| Gross profit | 30−71.2%12.7% | 105−32.2%29.6% | 155+70.2%39.9% | 91+185%41.5% | 32+2062%49.2% | 1.5—16.6% | |
| Research and development | 0.4+6.7%0.2% | 0.4−38.6%0.1% | 0.6−48.8%0.2% | 1.2−21.6%0.6% | 1.6−7.8%2.4% | 1.7—19.2% | |
| Selling and marketing | 54+1.8%22.7% | 53−5.8%15.0% | 57+144%14.5% | 23+175%10.6% | 8.4+213%13.0% | 2.7—30.2% | |
| Operating income | −67—−28.1% | −42−182%−11.7% | 51+79.6%13.0% | 28—12.8% | −38—−59.0% | −3.4—−38.3% | |
| Interest and finance income | 2.7−53.3%1.2% | 5.9−28.0%1.7% | 8.2+6185%2.1% | 0.1−79.0%0.1% | 0.6+340%1.0% | 0.1—1.6% | |
| Income before tax | −87—−36.6% | −61−240%−17.2% | 44+134%11.3% | 19—8.5% | −38—−58.9% | −6.6—−73.6% | |
| Income tax | −15−746%−6.1% | 2.2+2317%0.6% | 0.1−99.2%0.0% | 11—5.2% | −2.3—−3.5% | −0.7—−7.5% | |
| Net income including minority interests | −73—−30.5% | −64−245%−17.9% | 44+500%11.3% | 7.3—3.3% | −36—−55.4% | −5.9—−66.0% | |
| Minority interests' share of net income | −5.0—−2.1% | −1.6—−0.4% | −1.1−141%−0.3% | 2.6+119%1.2% | 1.2r−1.2—1.8% | — | |
| Net income attributable to shareholders | −68—−28.4% | −62−238%−17.4% | 45+856%11.5% | 4.7—2.1% | −37—−57.2% | −5.9—−66.0% | |
| Earnings per share, basic | -1.48—— | -1.36−237%— | 0.99+725%— | 0.12—— | -1.42—— | -0.25—— | |
| Earnings per share, diluted | -1.48—— | -1.36−237%— | 0.99+800%— | 0.11—— | -1.42—— | -0.25—— | |
| Shares, weighted average (basic) | 46+0.7%— | 46+0.5%— | 45+17.8%— | 38+51.6%— | 25+9.0%— | 23—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 78−22.6%10.3% | 101−56.5%12.9% | 233+18.5%24.3% | 196+418%28.2% | 38+38.6%11.6% | 27—9.7% | |
| Short-term investments | 0.3+78.1%0.0% | 0.2+19.1%0.0% | 0.2−52.4%0.0% | 0.3—0.0% | — | — | |
| Inventory | 120+14.1%15.8% | 105−24.7%13.4% | 140r120+125%14.6% | 62+227%8.9% | 19—5.8% | — | |
| Current assets | 392−6.4%51.4% | 419−20.6%53.2% | 527r507+56.9%55.1% | 336+339%48.3% | 77—23.5% | — | |
| Property, plant and equipment | 105+8.0%13.8% | 97−5.5%12.4% | 103+19.2%10.8% | 87+61.8%12.4% | 53—16.4% | — | |
| Goodwill | 225+1.6%29.5% | 221−22.2%28.1% | 284+5.9%29.7% | 268r258+41.1%38.5% | 190—58.3% | — | |
| Investments in associates | — | — | 40—4.2% | — | — | — | |
| Non-current assets | 371+0.8%48.6% | 368−10.4%46.8% | 411r451+13.9%42.9% | 360r350+44.4%51.7% | 250—76.5% | — | |
| Total assets | 763−3.1%100% | 787−17.9%100% | 958+37.5%100% | 697r686+113%100% | 326+15.6%100% | 282—100% | |
| Current liabilities | 227+0.4%29.7% | 226−27.8%28.7% | 313+61.5%32.6% | 194+548%27.8% | 30—9.2% | — | |
| Long-term debt | 114+38.7%14.9% | 82−17.5%10.5% | 100+739%10.4% | 12+2961%1.7% | 0.4—0.1% | — | |
| Lease liabilities (non-current) | 23+12.4%3.0% | 21−10.7%2.6% | 23+8.1%2.4% | 21+511%3.1% | 3.5—1.1% | — | |
| Non-current liabilities | 138+33.2%18.1% | 104−16.3%13.2% | 124+269%12.9% | 34+683%4.8% | 4.3—1.3% | — | |
| Total liabilities | 365+10.7%47.9% | 330−24.5%41.9% | 437+92.2%45.6% | 227+565%32.6% | 34—10.5% | −26—−9.2% | |
| Retained earnings | −278—−36.4% | −204—−25.9% | −142—−14.8% | −186—−26.8% | −191—−58.6% | — | |
| Shareholders' equity | 397−12.8%52.1% | 455−9.2%57.9% | 501+11.9%52.3% | 448+63.2%64.3% | 275—84.1% | — | |
| Minority interests | 0.7−64.0%0.1% | 2.0−90.3%0.2% | 20−5.7%2.1% | 21r11+21.5%3.1% | 18—5.4% | — | |
| Total equity | 398−13.0%52.1% | 457−12.4%58.1% | 521+11.1%54.4% | 469r459+60.7%67.4% | 292+14.0%89.5% | 256—90.8% | |
| Total liabilities and equity | 763−3.1%100% | 787−17.9%100% | 958+37.5%100% | 697r686+113%100% | 326—100% | — | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 15+16.7%6.4% | 13+12.5%3.7% | 12+58.2%3.0% | 7.4+127%3.4% | 3.3+293%5.0% | 0.8—9.3% | |
| Share-based compensation | 2.3−12.0%1.0% | 2.6−70.9%0.7% | 8.9+38.1%2.3% | 6.5−35.5%2.9% | 10−85.3%15.4% | 68—762% | |
| Cash from operating activities | −67—−28.0% | −54−205%−15.1% | 51+70.1%13.2% | 30r25+282%13.7% | 7.9r7.8—12.1% | −12—−130% | |
| Capital expenditure | −4.4—−1.8% | −2.6—−0.7% | −20—−5.1% | −14—−6.4% | −21—−32.0% | −28—−315% | |
| Acquisitions, net of cash acquired | — | — | — | −19—−8.7% | −0.4—−0.6% | −0.4—−4.3% | |
| Cash from investing activities | 18+271%7.4% | 4.8—1.3% | −142—−36.7% | −65—−29.7% | −23—−35.0% | −26—−292% | |
| Debt issued | 188+200%78.9% | 63−76.2%17.6% | 263+249%67.8% | 75+11247%34.3% | 0.7—1.0% | — | |
| Debt repaid | −175—−73.4% | −120—−33.7% | −121—−31.0% | −3.4—−1.6% | — | −0.2—−1.9% | |
| Cash from financing activities | 26—11.1% | −83−169%−23.3% | 120−39.2%31.0% | 198r203+686%90.1% | 25r25−60.2%38.7% | 63—708% | |
| Exchange-rate effect on cash | −0.0−113%−0.0% | 0.3−95.8%0.1% | 7.2—1.8% | −4.5−2152%−2.1% | 0.2—0.3% | −1.7—−18.6% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Intercure Ltd. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable segments(total)$78 M100%+21%
- Cannabis segment$78 M100%+21%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
How Intercure Ltd. compares in Biotechnology
- Market cap$51 M · higher than 27% of 726
- Revenue$65 M · higher than 63% of 647
- Net margin-28.4% · higher than 58% of 408
- Revenue growth-33.0% · higher than 26% of 438
- Price / sales0.8× · lower than 96% of 339
- Price / book0.5× · lower than 92% of 534
- FCF yield-37.4% · higher than 30% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Intercure Ltd.🇮🇱 | $51 M | — | -28.4% | -33.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Intercure Ltd.? Verify and update this profile — free
Show Intercure Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.